Trump Threatens To Impose Tariffs On Pharmaceuticals

Fierce Pharma reports:

As President Donald Trump renewed his threat of potential pharmaceutical tariffs this week, trade group the Biotechnology Innovation Organization (BIO) is warning of the fallout the additional duties could have on patients’ access to medicines.

Nearly 90% of U.S. biotech companies rely on some imported materials for at least half of their FDA-approved products, a BIO survey conducted in February has found.

The survey—which polled emerging drugmakers all the way up to commercial companies with $1 billion or more in annual revenue—reflected industrywide concerns that the tariffs floated by the White House could hurt access to affordable drugs, stall innovation and impose needless red tape, BIO said in a Wednesday release.

Read the full article.

🚨 Donald Trump singles out Ireland as he promises future tariffs on pharmaceutical imports, in an effort to bring drug manufacturing back to the U.S.

Ireland was “very smart” attracting that sector, he says.

Trump was speaking as he announced 25% tariffs on all imported cars pic.twitter.com/zzpTHenjYr

— Gavan Reilly (@gavreilly) March 27, 2025